Linked Life Data

16150858

Source:http://linkedlifedata.com/resource/pubmed/id/16150858

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-2-13
pubmed:abstractText
A 12 month, multicentre, randomised, double blind, placebo controlled, phase 3, dose-response study was carried out. Exisulind inhibits tumour growth by induction of apoptosis. The aim of our study was to investigate if exisulind induces regression of sporadic colonic adenomas.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-10048725, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-10369853, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-10656435, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-10799083, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-10910034, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-10982778, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-10982779, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-11026923, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-14568628, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-15239144, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-1650315, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-1659272, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-2073716, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-2535920, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-3653628, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-6887943, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-7698575, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-8140953, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-8213705, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-8247072, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-8379605, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-8385741, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-9135523, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-9192825, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-9219781, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-9230200, http://linkedlifedata.com/resource/pubmed/commentcorrection/16150858-9294096
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0017-5749
pubmed:author
pubmed:issnType
Print
pubmed:volume
55
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
367-73
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study.
pubmed:affiliation
Integrated Comprehensive Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Israel. nadir@tasmc.health.gov.il
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III